中國同輻(01763.HK):中核同源將在四川夾江建設放射源研發生產基地項目
格隆匯 4 月 15日丨中國同輻(01763.HK)宣佈,於2021年4月9日,中國同輻所屬四川中核同源科技有限公司(以下簡稱"中核同源")與夾江縣政府正式簽署投資協議,標誌着中國同輻放射源研發生產基地建設項目取得重要進展。
中國同輻放射源研發生產基地建設項目由成都中核高通同位素股份有限公司全資附屬公司四川中核同源科技有限公司籌建。根據公司發展戰略,中核同源將在四川夾江木城民用核技術產業園建設放射源研發生產基地項目。項目主要建設內容包括放射源研發中心、輻照技術應用中心、物流中心及其配套設施,建成後將成為國內最先進,國際領先的放射源產業基地。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.